Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.67 |
| ▸ | MEN1 | O00255 | 9/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 8/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688917 | 0.90 | MEN1 (0.58) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL4688915 | 0.90 | MEN1 (0.58) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL4687906 | 0.85 | MEN1 (0.58) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL4687907 | 0.85 | MEN1 (0.58) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL9367406 | 0.82 | KMT2A (0.77) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL4232078 | 0.82 | KMT2A (0.55) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL13915770 | 0.81 | MAPT (0.57) | KMT2AMEN1GAAPKMMAPT | |
| SCHEMBL4787488 | 0.81 | TBXA2R (0.61) | KMT2AMEN1MAPTPOLBMAPK1 | |
| SCHEMBL3139234 | 0.80 | KMT2A (0.74) | KMT2AMEN1GAAPKMATM | |
| SCHEMBL13915773 | 0.80 | TLR9 (0.59) | KMT2AMEN1MAPTPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
| US-7253184-B2 | 4-Substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027054-A1 | 4-Substituted quinolines as antitumor agents | CCNY, TPD52L2, H1-10 | KMT2A 959/4885MEN1 953/4885GAA 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.